ciclesonide + beclomethasone dipropionate (Allegheny Health Network)

Alvesco + Omnaris + Qvar + Beconase refers to a specific clinical trial grouping (NCT01550471) comparing two corticosteroid treatment regimens in pediatric patients with mild asthma and allergic rhinitis. The first regimen utilizes ciclesonide, delivered as Alvesco (inhaled aerosol) and Omnaris (nasal spray). The second regimen utilizes beclomethasone dipropionate, delivered as Qvar (inhaled aerosol) and Beconase AQ (nasal spray). Both active ingredients are small molecule glucocorticoid receptor agonists that exert anti-inflammatory effects in the respiratory and nasal mucosa. Ciclesonide is a prodrug that is converted to its active metabolite, des-ciclesonide, locally in the lungs and nose, which is hypothesized to minimize systemic exposure and associated side effects such as growth suppression. The trial, sponsored by the Allegheny Health Network, used knemometry to measure short-term lower leg growth as a sensitive marker for systemic corticosteroid activity in children.

Brand names

Beconase AQ

Other names

Alvesco + Omnaris + Qvar + Beconase